Last week independent Senators Bernie Sanders (VT) and Angus King (ME) introduced legislation that would ban pharmaceutical companies from promoting prescription drugs directly to consumers - including through television, radio, print, digital platforms, and social media. 

Today, Bloomberg reports that the Trump administration is now 'discussing policies that would make it harder and more expensive for pharmaceutical companies to advertise directly to patients.'

Although the US is the only place, besides New Zealand, where pharma companies can directly advertise, banning pharma ads outright could make the administration vulnerable to lawsuits, so it's instead focusing on cutting down on the practice by adding legal and financial hurdles, according to people familiar with the plans who weren't authorized to speak publicly on the matter.

The two policies the administration has focused in on would be to require greater disclosures of side effects of a drug within each ad — likely making broadcast ads much longer and prohibitively expensive — or removing the industry's ability to deduct direct-to-consumer advertising as a business expense for tax purposes, these people said.